Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States

View ORCID ProfileKaitlin Rainwater-Lovett, John T. Redd, Miles A. Stewart, Natalia Elías Calles, Tyler Cluff, Mike Fang, Mark J. Panaggio, Anastasia S. Lambrou, Jonathan K. Thornhill, Christopher Bradburne, Samuel Imbriale, Jeffrey D. Freeman, Michael Anderson, Robert Kadlec
doi: https://doi.org/10.1101/2021.04.08.21254705
Kaitlin Rainwater-Lovett
1Asymmetric Operations Sector, Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland
2Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kaitlin Rainwater-Lovett
  • For correspondence: Kaitlin.Lovett@jhuapl.edu
John T. Redd
2Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: John.Redd@hhs.gov
Miles A. Stewart
1Asymmetric Operations Sector, Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland
2Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalia Elías Calles
3Tucson Medical Center, TMC HealthCare, Tucson, Arizona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tyler Cluff
3Tucson Medical Center, TMC HealthCare, Tucson, Arizona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike Fang
1Asymmetric Operations Sector, Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. Panaggio
1Asymmetric Operations Sector, Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anastasia S. Lambrou
1Asymmetric Operations Sector, Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland
2Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan K. Thornhill
1Asymmetric Operations Sector, Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland
2Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Bradburne
1Asymmetric Operations Sector, Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland
4McKusick-Nathans Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel Imbriale
2Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey D. Freeman
1Asymmetric Operations Sector, Johns Hopkins University Applied Physics Laboratory, Laurel, Maryland
2Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Anderson
2Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Kadlec
2Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Monoclonal antibodies (mAbs) against SARS-CoV-2 are a promising treatment for limiting the progression of COVID-19 and decreasing strain on hospitals. Their use, however, remains limited, particularly in disadvantaged populations.

Methods Electronic health records were reviewed from SARS-CoV-2 patients at a single medical center in the United States that initiated mAb infusions in January 2021 with the support of the U.S. Department of Health and Human Services’ National Disaster Medical System. Patients who received mAbs were compared to untreated patients from the time period before mAb availability who met eligibility criteria for mAb treatment. We used logistic regression to measure the effect of mAb treatment on the risk of hospitalization or emergency department (E.D.) visit within 30 days of laboratory-confirmed COVID-19.

Results Of 598 COVID-19 patients, 270 (45%) received bamlanivimab and 328 (55%) were untreated. Two hundred and thirty-one patients (39%) were Hispanic. Among treated patients, 5/270 (1.9%) presented to the E.D. or required hospitalization within 30 days of a positive SARS-CoV-2 test, compared to 39/328 (12%) untreated patients (p<0.001). After adjusting for age, gender, and comorbidities, the risk of E.D. visit or hospitalization was 82% lower in mAb-treated patients compared to untreated patients (95% confidence interval [CI]: 66%-94%).

Conclusions In this diverse, real-world COVID-19 patient population, mAb treatment significantly decreased the risk of subsequent E.D. visit or hospitalization. Broader treatment with mAbs, including in disadvantaged patient populations, can decrease the burden on hospitals and should be facilitated in all populations in the United States to ensure health equity.

Summary In a diverse, real-world COVID-19 patient population, treatment with monoclonal antibodies significantly decreased the risk of subsequent emergency department visit or hospitalization within 30 days of a positive SARS-CoV-2 viral test.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

All authors have completed the ICMJE uniform disclosure form: all authors had financial support from the U.S. Department of Health and Human Services, Office of the Assistant Secretary of Preparedness and Response for the submitted work. The authors or their institutions did not receive payment or services from a third party for any aspect of the submitted work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This clinical support activity was conducted as part of the Office of the Assistant Secretary of Preparedness and Response's public health response to the COVID-19 pandemic and at the request of the host medical center. Under the Department of Health and Human Services Office of Health Research Protection guidelines, it was judged a non-research COVID-19 response. The Johns Hopkins University Applied Physics Laboratory and the medical center concurred with a non-research determination.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data was used from electronic medical records as part of process improvement and is not publicly available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 13, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States
Kaitlin Rainwater-Lovett, John T. Redd, Miles A. Stewart, Natalia Elías Calles, Tyler Cluff, Mike Fang, Mark J. Panaggio, Anastasia S. Lambrou, Jonathan K. Thornhill, Christopher Bradburne, Samuel Imbriale, Jeffrey D. Freeman, Michael Anderson, Robert Kadlec
medRxiv 2021.04.08.21254705; doi: https://doi.org/10.1101/2021.04.08.21254705
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States
Kaitlin Rainwater-Lovett, John T. Redd, Miles A. Stewart, Natalia Elías Calles, Tyler Cluff, Mike Fang, Mark J. Panaggio, Anastasia S. Lambrou, Jonathan K. Thornhill, Christopher Bradburne, Samuel Imbriale, Jeffrey D. Freeman, Michael Anderson, Robert Kadlec
medRxiv 2021.04.08.21254705; doi: https://doi.org/10.1101/2021.04.08.21254705

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (161)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (860)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (250)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8562)
  • Forensic Medicine (4)
  • Gastroenterology (384)
  • Genetic and Genomic Medicine (1753)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1244)
  • Health Policy (621)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (374)
  • Infectious Diseases (except HIV/AIDS) (10303)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (212)
  • Neurology (1678)
  • Nursing (97)
  • Nutrition (251)
  • Obstetrics and Gynecology (326)
  • Occupational and Environmental Health (451)
  • Oncology (929)
  • Ophthalmology (263)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (536)
  • Pharmacology and Therapeutics (253)
  • Primary Care Research (208)
  • Psychiatry and Clinical Psychology (1770)
  • Public and Global Health (3841)
  • Radiology and Imaging (624)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (520)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)